AR024742A1 - DERIVADOS CICLOPEPTIDICOS QUE ACTUAN COMO INHIBIDORES DE LA INTEGRINA ALFA v BETA 6, LOS MEDICAMENTOS A BASE DE ESTOS COMPUESTOS, LAS COMPOSICIONESFARMACEUTICAS QUE CONTIENEN AL MENOS UNO DE ESTOS MEDICAMENTOS, Y EL EMPLEO DE ESTOS PEPTIDOS PARA PREPARAR UN MEDICAMENTO. - Google Patents
DERIVADOS CICLOPEPTIDICOS QUE ACTUAN COMO INHIBIDORES DE LA INTEGRINA ALFA v BETA 6, LOS MEDICAMENTOS A BASE DE ESTOS COMPUESTOS, LAS COMPOSICIONESFARMACEUTICAS QUE CONTIENEN AL MENOS UNO DE ESTOS MEDICAMENTOS, Y EL EMPLEO DE ESTOS PEPTIDOS PARA PREPARAR UN MEDICAMENTO.Info
- Publication number
- AR024742A1 AR024742A1 ARP000103621A ARP000103621A AR024742A1 AR 024742 A1 AR024742 A1 AR 024742A1 AR P000103621 A ARP000103621 A AR P000103621A AR P000103621 A ARP000103621 A AR P000103621A AR 024742 A1 AR024742 A1 AR 024742A1
- Authority
- AR
- Argentina
- Prior art keywords
- compounds
- derivatives
- cyclopeptidic
- medications
- permitted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Derivados ciclopeptídicos de formula 1 ciclo-(Arg-X1-Asp-X2-X3-X4-X5-X6-R1) en donde X1 representa Ser, Gli o Tr, X2 representa Leu, Ile, Nle, Val o Fen,X3 representa Asp, Glu, Lis, o Fen, X4 representa Gli, Ala o Ser, X5 representa Leu, Ile, Nle, Val o Fen, X6 representa Arg, Har o Lis, R1 está ausente orepresenta uno o varios radicales de ácido omega-amino-carboxílico, presentando el/o los radical/es de ácido omega-aminocarboxílico una longitud de 500 a2500 pm,y en donde los aminoácidos mencionados también pueden estar derivatizados, e incluyendo tanto las formas D como las formas L de los radicales deaminoácido opticamente activos, y los solvatos y las sales aceptables desde el punto de vista fisiologico de estos compuestos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19933173A DE19933173A1 (de) | 1999-07-15 | 1999-07-15 | Cyclische Peptidderivate als Inhibitoren des Integrins alpha¶v¶beta¶6¶ |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR024742A1 true AR024742A1 (es) | 2002-10-23 |
Family
ID=7914891
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP000103621A AR024742A1 (es) | 1999-07-15 | 2000-07-14 | DERIVADOS CICLOPEPTIDICOS QUE ACTUAN COMO INHIBIDORES DE LA INTEGRINA ALFA v BETA 6, LOS MEDICAMENTOS A BASE DE ESTOS COMPUESTOS, LAS COMPOSICIONESFARMACEUTICAS QUE CONTIENEN AL MENOS UNO DE ESTOS MEDICAMENTOS, Y EL EMPLEO DE ESTOS PEPTIDOS PARA PREPARAR UN MEDICAMENTO. |
Country Status (23)
| Country | Link |
|---|---|
| EP (2) | EP1754714A1 (es) |
| JP (1) | JP2003505395A (es) |
| KR (1) | KR20020010928A (es) |
| CN (1) | CN1361792A (es) |
| AR (1) | AR024742A1 (es) |
| AT (1) | ATE340803T1 (es) |
| AU (1) | AU772782C (es) |
| BR (1) | BR0012418A (es) |
| CA (1) | CA2379022A1 (es) |
| CZ (1) | CZ200226A3 (es) |
| DE (2) | DE19933173A1 (es) |
| DK (1) | DK1196433T3 (es) |
| ES (1) | ES2273703T3 (es) |
| HK (1) | HK1048641A1 (es) |
| HU (1) | HUP0201925A3 (es) |
| MX (1) | MXPA02000465A (es) |
| NO (1) | NO20020176D0 (es) |
| PL (1) | PL354363A1 (es) |
| PT (1) | PT1196433E (es) |
| SK (1) | SK262002A3 (es) |
| TW (1) | TWI226890B (es) |
| WO (1) | WO2001005810A2 (es) |
| ZA (1) | ZA200201275B (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2438663C (en) * | 2001-02-19 | 2009-09-15 | Takara Bio Inc. | Cyclic peptide |
| DE10118550A1 (de) * | 2001-04-14 | 2002-10-17 | Merck Patent Gmbh | Liganden des Integrins alpha¶nu¶beta¶6¶ |
| DE602004014795D1 (de) * | 2003-10-01 | 2008-08-14 | Merck Patent Gmbh | Alfavbeta3 und alfavbeta6 integrin antagonisten als antifibrotische mittel |
| CA2548243A1 (en) * | 2003-12-03 | 2005-06-23 | The Scripps Research Institute | Integrin aiib.beta.3 specific antibodies and peptides |
| EP1812037A4 (en) | 2004-10-06 | 2009-11-11 | Amr Technology Inc | ALKYNES OF CYCLOSPORINE AND THEIR USEFUL AS PHARMACEUTICAL AGENTS |
| GB0520068D0 (en) | 2005-10-03 | 2005-11-09 | Cancer Res Technology | av peptide ligand |
| US7696166B2 (en) | 2006-03-28 | 2010-04-13 | Albany Molecular Research, Inc. | Use of cyclosporin alkyne/alkene analogues for preventing or treating viral-induced disorders |
| US7696165B2 (en) | 2006-03-28 | 2010-04-13 | Albany Molecular Research, Inc. | Use of cyclosporin alkyne analogues for preventing or treating viral-induced disorders |
| RU2009107277A (ru) | 2006-08-03 | 2010-09-10 | Астразенека Аб (Se) | АНТИТЕЛА, НАЦЕЛЕННЫЕ НА αVβ6, И ИХ ПРИМЕНЕНИЕ |
| EP2784511A1 (en) | 2013-03-27 | 2014-10-01 | Universität Zürich | Integrin alpha-v-beta6 for diagnosis/prognosis of colorectal carcinoma |
| WO2017046416A1 (en) | 2015-09-18 | 2017-03-23 | Technische Universität München | LIGANDS FOR INTEGRIN AVß6, SYNTHESIS AND USES THEREOF |
| EP3589627A4 (en) | 2017-02-28 | 2020-08-05 | Morphic Therapeutic, Inc. | INHIBITORS OF (ALPHA-V) (BETA-6) -INTEGRIN |
| US11046685B2 (en) | 2017-02-28 | 2021-06-29 | Morphic Therapeutic, Inc. | Inhibitors of (α-v)(β-6) integrin |
| WO2018167295A1 (en) | 2017-03-17 | 2018-09-20 | Technische Universität München | LIGANDS FOR INTEGRIN αvβ8, SYNTHESIS AND USES THEREOF |
| GB201706472D0 (en) * | 2017-04-24 | 2017-06-07 | Cancer Res Tech Ltd | Tumour-targeting peptide variants |
| PE20211640A1 (es) | 2018-08-29 | 2021-08-24 | Morphic Therapeutic Inc | INHIBICION DE LA INTEGRINA xvß6 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4472305A (en) | 1983-05-17 | 1984-09-18 | Sterling Drug Inc. | Hexapeptide amides |
| DE4310643A1 (de) | 1993-04-01 | 1994-10-06 | Merck Patent Gmbh | Cyclische Adhäsionsinhibitoren |
| DE19538741A1 (de) | 1995-10-18 | 1997-04-24 | Merck Patent Gmbh | Cyclopeptidderivate |
| CN1335853A (zh) * | 1998-12-19 | 2002-02-13 | 默克专利股份公司 | 整联蛋白αvβb的抑制剂 |
-
1999
- 1999-07-15 DE DE19933173A patent/DE19933173A1/de not_active Withdrawn
-
2000
- 2000-07-03 HU HU0201925A patent/HUP0201925A3/hu unknown
- 2000-07-03 CA CA002379022A patent/CA2379022A1/en not_active Abandoned
- 2000-07-03 CN CN00810415A patent/CN1361792A/zh active Pending
- 2000-07-03 ES ES00943971T patent/ES2273703T3/es not_active Expired - Lifetime
- 2000-07-03 EP EP06019918A patent/EP1754714A1/de not_active Withdrawn
- 2000-07-03 JP JP2001511467A patent/JP2003505395A/ja active Pending
- 2000-07-03 CZ CZ200226A patent/CZ200226A3/cs unknown
- 2000-07-03 DK DK00943971T patent/DK1196433T3/da active
- 2000-07-03 AU AU58236/00A patent/AU772782C/en not_active Ceased
- 2000-07-03 MX MXPA02000465A patent/MXPA02000465A/es unknown
- 2000-07-03 DE DE50013525T patent/DE50013525D1/de not_active Expired - Fee Related
- 2000-07-03 EP EP00943971A patent/EP1196433B1/de not_active Expired - Lifetime
- 2000-07-03 PT PT00943971T patent/PT1196433E/pt unknown
- 2000-07-03 AT AT00943971T patent/ATE340803T1/de not_active IP Right Cessation
- 2000-07-03 WO PCT/EP2000/006188 patent/WO2001005810A2/de active IP Right Grant
- 2000-07-03 KR KR1020017015995A patent/KR20020010928A/ko not_active Application Discontinuation
- 2000-07-03 BR BR0012418-4A patent/BR0012418A/pt not_active Application Discontinuation
- 2000-07-03 SK SK26-2002A patent/SK262002A3/sk unknown
- 2000-07-03 PL PL00354363A patent/PL354363A1/xx unknown
- 2000-07-13 TW TW089113997A patent/TWI226890B/zh not_active IP Right Cessation
- 2000-07-14 AR ARP000103621A patent/AR024742A1/es unknown
-
2002
- 2002-01-14 NO NO20020176A patent/NO20020176D0/no unknown
- 2002-02-14 ZA ZA200201275A patent/ZA200201275B/xx unknown
-
2003
- 2003-01-15 HK HK03100378.9A patent/HK1048641A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NO20020176L (no) | 2002-01-14 |
| WO2001005810A2 (de) | 2001-01-25 |
| EP1754714A1 (de) | 2007-02-21 |
| PL354363A1 (en) | 2004-01-12 |
| KR20020010928A (ko) | 2002-02-06 |
| CA2379022A1 (en) | 2001-01-25 |
| TWI226890B (en) | 2005-01-21 |
| CZ200226A3 (cs) | 2002-04-17 |
| MXPA02000465A (es) | 2002-07-30 |
| ATE340803T1 (de) | 2006-10-15 |
| HK1048641A1 (zh) | 2003-04-11 |
| HUP0201925A2 (en) | 2002-10-28 |
| AU772782C (en) | 2005-01-27 |
| EP1196433B1 (de) | 2006-09-27 |
| NO20020176D0 (no) | 2002-01-14 |
| DE50013525D1 (de) | 2006-11-09 |
| ZA200201275B (en) | 2003-08-22 |
| DE19933173A1 (de) | 2001-01-18 |
| DK1196433T3 (da) | 2007-02-12 |
| AU5823600A (en) | 2001-02-05 |
| BR0012418A (pt) | 2002-03-26 |
| JP2003505395A (ja) | 2003-02-12 |
| ES2273703T3 (es) | 2007-05-16 |
| WO2001005810A3 (de) | 2001-05-17 |
| CN1361792A (zh) | 2002-07-31 |
| HUP0201925A3 (en) | 2002-11-28 |
| AU772782B2 (en) | 2004-05-06 |
| SK262002A3 (en) | 2002-07-02 |
| PT1196433E (pt) | 2007-01-31 |
| EP1196433A2 (de) | 2002-04-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR024742A1 (es) | DERIVADOS CICLOPEPTIDICOS QUE ACTUAN COMO INHIBIDORES DE LA INTEGRINA ALFA v BETA 6, LOS MEDICAMENTOS A BASE DE ESTOS COMPUESTOS, LAS COMPOSICIONESFARMACEUTICAS QUE CONTIENEN AL MENOS UNO DE ESTOS MEDICAMENTOS, Y EL EMPLEO DE ESTOS PEPTIDOS PARA PREPARAR UN MEDICAMENTO. | |
| MX9207334A (es) | Acidos nucleicos peptidicos y formulacion farma- ceutica que los contiene | |
| PT1086706E (pt) | Composicao estabilizada que compreende um medicamento nootropico | |
| UY27446A1 (es) | Nuevos compuestos | |
| AR005152A1 (es) | Amidas tricíclicas útiles para la inhibición de la función de la proteina-g, sus sales , una composición farmacéutica que las contienen y el uso de las mismas para la fabricación de un medicamento para el tratamiento de enfermedades proliferativas | |
| NO20010995D0 (no) | Cytotoksiske peptider modifisert med store eller lipofile rester | |
| CO4890856A1 (es) | CICATRIZACION DE FRACTURAS USANDO ANALOGOS DE PTHrP | |
| DE69428040T2 (de) | Orale darreichungsform | |
| CO4790174A1 (es) | Analogos del peptido lh-rh, sus usos y composiciones farmaceuticas que los contienen | |
| AR019853A1 (es) | Derivado del acido 3-aril-2-hidroxipropionico, proceso e intermediario para su preparacion, formulaciones farmaceuticas, uso de dicho compuesto en laelaboracion de un medicamento, metodo para la profilaxis y/o tratamiento de trastornos clinicos asociados con la resistencia a la insulina, y formulaci | |
| AR006569A1 (es) | Derivados de acidos carboxilicos, medicamentos que contienen estos compuestos, su utilizacion y procedimientos para su preparacion | |
| AR013079A1 (es) | Derivados sustituidos de tetrahidrofurano-3-onas, de tetrahidropirano-3- onas y tetrahidrotiofen-3-onas, un procedimiento para su preparacion unacomposicion farmaceutica de un medicamento util como inhibidores de proteasas e intermediarios | |
| DE50005529D1 (de) | Orale darreichungsformen zur verabreichung einer fixen kombination von tramadol und diclofenac | |
| ES2062100T3 (es) | Empleo de acetil l-carnitina en el tratamiento terapeutico de cataratas y composiciones farmaceuticas utiles en este tratamiento. | |
| DE69525955T2 (de) | Ein wachstumshormon und isoleucin enthaltende pharmazeutische formulierung | |
| AR049651A1 (es) | Compuesto de dicetopiperazina, composicion farmaceutica que lo comprende, uso del compuesto para la fabricacion de un medicamento y procedimiento para la preparacion del mismo | |
| ATE172721T1 (de) | Aminosäurederivate und ihre verwendung als enkephalinase-inhibitoren | |
| AR011437A1 (es) | Composicion farmaceutica para el tratamiento de la migrana y el uso de la misma en la preparacion de un medicamento. | |
| AR020101A1 (es) | Un antagonista peptido del receptor de uroquinasa humana, composicion farmaceutica que lo contiene, su uso para la manufactura de un medicamento y metodopara seleccionar un antagonista peptido adecuado. | |
| BR0206960A (pt) | Composição farmacêutica oral, e, uso de um polìmero de ftalato de hidroxipropilmetilcelulose | |
| ID21282A (id) | Senyawa-senyawa cincin beranggota-5 terpadu yang disubstitusi sulfonamida, penggunaannya sebagai obat, dan sediaan farmasi yang mengandung senyawa tersebut | |
| ES2172594T3 (es) | Una formulacion farmaceutica que comprende una hormona de crecimiento y leucina. | |
| HUP0300651A2 (hu) | Nátrium-hidrogén-cserélő 1-es típusú inhibitor (NHE-1) alkalmazása gyógyszerkészítmények előállítására és ezt tartalmazó gyógyszerkészítmények | |
| ATE270551T1 (de) | Kombinationspräparat aus 2-methylthiazolidin-2,4- dicarbonsäure und paracetamol | |
| BR0015170A (pt) | Proteìnas de hcv com oxirredução reversìvel e conformação similar à nativa |